Frankfurt - Delayed Quote EUR

Seres Therapeutics, Inc. (1S9.F)

Compare
0.8502
+0.0330
+(4.04%)
At close: January 10 at 8:36:50 AM GMT+1

Research Analysis

Revenue vs. Earnings

Revenue --
Earnings 88.78M
Q4'23
Q1'24
Q2'24
Q3'24
0
50M
 

Analyst Price Targets

Earnings Estimate

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts --------
Avg. Estimate 0000
Low Estimate 0000
High Estimate 0000
Year Ago EPS --------

Revenue Estimate

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts 6467
Avg. Estimate --12.5M--29.86M
Low Estimate --------
High Estimate --50M--125M
Year Ago Sales 64k--126.33M--
Sales Growth (year/est) -100.00%0.00%-100.00%0.00%

EPS Trend

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Current Estimate 0000
7 Days Ago 0000
30 Days Ago 0000
60 Days Ago 0000
90 Days Ago 0000

EPS Revisions

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days --------

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
1S9.F --------
S&P 500 8.66%11.51%14.05%13.39%

Upgrades & Downgrades

Maintains Canaccord Genuity: Buy to Buy 11/14/2024
Maintains Chardan Capital: Buy to Buy 11/13/2024
Downgrade JP Morgan: Neutral to Underweight 10/24/2024
Maintains Canaccord Genuity: Buy to Buy 9/13/2024
Maintains Canaccord Genuity: Buy to Buy 8/14/2024
Maintains Chardan Capital: Buy to Buy 8/14/2024

Related Tickers